CoChat

Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit

Open access
Zhu, Zehua, Aref, Amir R., Cohoon, Travis J., Barbie, Thanh U., Imamura, Yu, Yang, Shenghong, Moody, Susan E., Shen, Rhine R., Schinzel, Anna C., Thai, Tran C., Reibel, Jacob B., Tamayo, Pablo, Godfrey, Jason T., Qian, Zhi Rong, Page, Asher N., Maciag, Karolina, Chan, Edmond M., Silkworth, Whitney, Labowsky, Mary T., Rozhansky, Lior, Mesirov, Jill P., Gillanders, William E., Ogino, Shuji, Hacohen, Nir, Gaudet, Suzanne, Eck, Michael J., Engelman, Jeffrey A., Corcoran, Ryan B., Wong, Kwok-Kin, Hahn, William C., Barbie, David A. · 2014 · Cancer Discovery
Cited by 192

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Although the roles of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling in KRAS-driven tumorigenesis are well established, KRAS activates additional pathways required for tumor maintenance, the inhibition of which are likely to be necessary for effective KRAS-directed therapy. Here, we show that the IκB kinase (IKK)–related kinases Tank-binding kinase-1 (TBK1) and IKKϵ promote KRAS-driven tumorigenesis by regulating autocrine CCL5 and interleukin (IL)-6 and identify CYT387 as a potent JAK/TBK1/IKKϵ inhibitor. CYT387 treatment ablates RAS-associated cytokine signaling and impairs Kras-driven murine lung cancer growth. Combined CYT387 treatment and MAPK pathway inhibition induces regression of aggressive murine lung adenocarcinomas driven by Kras mutation and p53 loss. These observations reveal that TBK1/IKKϵ promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKKϵ, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS. Significance: In addition to activating MAPK and PI3K, oncogenic KRAS engages cytokine signaling to promote tumorigenesis. CYT387, originally described as a selective JAK inhibitor, is also a potent TBK/IKKϵ inhibitor that uniquely disrupts a cytokine circuit involving CCL5, IL-6, and STAT3. The efficacy of CYT387-based treatment in murine Kras-driven lung cancer models uncovers a novel therapeutic approach for these refractory tumors with immediate translational implications. Cancer Discov; 4(4); 452–65. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 377

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0646

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 192

Metadata

Authors
Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., Reibel, J. B., Tamayo, P., Godfrey, J. T., Qian, Z. R., Page, A. N., Maciag, K., Chan, E. M., Silkworth, W., Labowsky, M. T., Rozhansky, L., Mesirov, J. P., Gillanders, W. E., Ogino, S., Hacohen, N., Gaudet, S., Eck, M. J., Engelman, J. A., Corcoran, R. B., Wong, K.-K., Hahn, W. C., & Barbie, D. A.
Venue
Cancer Discovery
Published
2014-04-01
Volume
4
Issue
4
Pages
452-465
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2160371778
Cited by
192
References
11
FWCI
7.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0646
The paper
Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., Reibel, J. B., Tamayo, P., Godfrey, J. T., Qian, Z. R., Page, A. N., Maciag, K., Chan, E. M., Silkworth, W., Labowsky, M. T., . . . Barbie, D. A. (2014). Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0646

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.